Metabolomics is providing increasingly detailed insights into the complex relationship between metabolism, disease, and human health. The latest edition of the Metabolomics Industry Focus eBook explores advances in metabolomics, lipidomics, and multi-omics research, exploring how these approaches help researchers better understand biological processes, identify disease mechanisms, and uncover potential biomarkers.
About this eBook
This edition brings together expert articles examining the growing applications of metabolomics across biomedical and life science research. Readers will learn more about how untargeted metabolomics and lipidomics can reveal previously hidden biological insights, alongside developments in single-cell analysis and multi-omics profiling.
The eBook also highlights the role of metabolic and molecular profiling in understanding complex diseases and health outcomes, including cognitive aging, colorectal cancer, cardiovascular disease, autoimmune disorders, and Alzheimer’s disease. Further research highlights how blood chemistry, gut microbiota, and metabolic signatures could help uncover connections between lifestyle, disease risk, and individual patient biology.
Whether you work in metabolomics, drug discovery, biomarker research, precision medicine, or systems biology, this eBook provides valuable insight into the technologies and research shaping our understanding of metabolism and disease.
About Evotec
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure – faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec’s global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us LinkedIn and X/Twitter @Evotec.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.